Auven Therapeutics

Auven Therapeutics is a private equity firm that focuses on acquiring and advancing the development of promising therapeutic drugs, particularly in the healthcare sector. The firm specializes in taking controlling ownership of therapeutic products or platforms, enhancing their value through comprehensive development programs, and subsequently licensing them to established pharmaceutical companies. Founded in 2007 by Stephen Evans-Freke and Dr. Peter B. Corr, Auven Therapeutics operates globally, with offices in the U.S. Virgin Islands, Switzerland, the United Kingdom, Bermuda, and the United States.

The firm's investment strategy encompasses a diverse portfolio of biologic and small molecule therapeutic candidates targeting critical unmet medical needs across various therapeutic areas, including oncology, ophthalmology, women's health, and orphan diseases. Auven Therapeutics has ownership or controlling interests in several therapeutic assets, such as ADC Therapeutics, Spirogen, Resolvyx, and Kiacta, and holds minority investments in Kolltan and Sprout Pharmaceuticals. This diversified approach enables the firm to address a wide range of medical conditions through its investments.

Auven Therapeutics' in-house team of senior pharmaceutical development executives is integral to its operations, establishing and overseeing the clinical, regulatory, manufacturing, and commercial strategies for all its products. This hands-on approach ensures that the firm effectively manages the development process, from initial acquisition through to commercialization, thereby maximizing the potential value of its therapeutic assets. The firm's global presence and strategic partnerships further enhance its ability to navigate the complex landscape of pharmaceutical development and commercialization.